Trials / Completed
CompletedNCT02940314
Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers
A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the safety and pharmacokinetic characteristics after administration of HIP1503 and HGP1103 in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HIP1503 | |
| DRUG | HGP1103 |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2016-10-20
- Last updated
- 2016-10-20
Source: ClinicalTrials.gov record NCT02940314. Inclusion in this directory is not an endorsement.